Patent · US Active

Treatment of complement-associated disorders

US8007798B2 · kind B2 · utility

26Cited by

12References

47Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Avi Ashkenazi · San Mateo, US
Karim Yussef Helmy · San Francisco, US
Sherman Fong · Alameda, US
Audrey Goddard · San Francisco, US
Austin Gurney · Belmont, US
Kenneth Katschke · Fairfield, US
Menno Van Lookeren · San Francisco, US
William I. Wood · Hillsborough, US

Key dates

Filing date	Oct 12, 2005
Grant date	Aug 30, 2011
Priority date	—
Expiry date	Dec 29, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.